FDA approves new drug to prevent repeat strokes
The US Food and Drug Administration approved a new blood thinner to stop repeat strokes in patients who recently suffered a serious event.
Bayer developed asundexian to block a specific protein called Factor XIa that causes dangerous clotting and vessel blockage in human bodies. This unique approach differs from existing medications that target a completely different protein known as Factor Xa for treating various health conditions.
The approval followed positive results from a worldwide Phase 3 study regarding blood clots. The drug serves as an oral once-daily treatment designed to reduce the risk of secondary stroke when combined with standard therapy.
Experts estimate that one in five stroke patients will experience another episode within five years. Ashkan Shoamanesh from the Population Health Research Institute believes this drug brings a vital new option to post-stroke care strategies globally.
Approximately 800,000 Americans face stroke annually. Secondary strokes remain more dangerous than initial episodes for many patients suffering from serious health issues today now. This fact highlights the need for effective prevention.

